This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
GHK-Cu (Copper Tripeptide) GHK-Cu, or copper tripeptide-1, is a naturally occurring peptide with high affinity for copper ions
Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons
10.4081/dr.2022.9188 163
Therapeutic focus: Cagrilintide is being studied specifically for weight management, appetite suppression, and improved glycemic control, both alone and in combination with GLP-1 receptor agonists like semaglutide
